{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:48Z","timestamp":1792552308852,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40265-020-01318-8","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T15:03:43Z","timestamp":1588863823000},"page":"835-840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Tirabrutinib: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"1318_CR1","unstructured":"Ono Pharmaceutical. ONO Receives a Manufacturing and Marketing Approval for Velexbru\u00ae tablet 80\u00a0mg, a BTK inhibitor, for treatment of recurrent or refractory primary central nervous system lymphoma in Japan [media release]. https:\/\/www.ono.co.jp\/eng\/news\/pdf\/sm_cn200325.pdf. Accessed 25 Mar 2020."},{"key":"1318_CR2","unstructured":"Ono Pharmaceutical Co. VELEXBRU\u24c7 (Tirabrutinib) 80\u00a0mg tablets: Japanese prescribing information. 2020. https:\/\/www.pmda.go.jp\/. Accessed 14 Apr 2020."},{"key":"1318_CR3","unstructured":"Ono Pharmaceutical. ONO submits an application for Manufacturing and Marketing Approval in Japan for tirabrutinib hydrochloride (ONO-4059), a BTK inhibitor, for the treatment of Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma [media release]. https:\/\/www.ono.co.jp\/eng\/news\/pdf\/sm_cn191127.pdf. Accessed 27 Nov 2019."},{"key":"1318_CR4","unstructured":"Ono Pharmaceutical. ONO and Gilead announce exclusive license agreement to develop BTK inhibitor, ONO-4059, for the treatment of B-cell alignancies and other diseases [media release]. https:\/\/www.ono.co.jp\/eng\/news\/pdf\/sm_cn141219.pdf. Accessed 19 Dec 2014."},{"issue":"4","key":"1318_CR5","doi-asserted-by":"publisher","first-page":"129531","DOI":"10.1016\/j.bbagen.2020.129531","volume":"1864","author":"A Liclican","year":"2020","unstructured":"Liclican A, Serafini L, Xing W, et al. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on- and off- target inhibition. Biochim Biophys Acta Gen Subj. 2020;1864(4):129531.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"4","key":"1318_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/cancers10040127","volume":"10","author":"R Kozaki","year":"2018","unstructured":"Kozaki R, Vogler M, Walter HS, et al. Responses to the selective Bruton's tyrosine kinase (BTK) inhibitor tirabrutinib (ONO\/GS-4059) in diffuse large B-cell lymphoma cell lines. Cancers (Basel). 2018;10(4):127. https:\/\/doi.org\/10.3390\/cancers10040127.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"1318_CR7","doi-asserted-by":"publisher","first-page":"e0171221","DOI":"10.1371\/journal.pone.0171221","volume":"12","author":"A Yahiaoui","year":"2017","unstructured":"Yahiaoui A, Meadows SA, Sorensen RA, et al. PI3K\u03b4 inhibitor idelalisib in combination with BTK inhibitor ONO\/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K\u03b4 and BTK inhibitors. PLoS ONE. 2017;12(2):e0171221.","journal-title":"PLoS ONE"},{"issue":"3","key":"1318_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/10428194.2016.1201567","volume":"58","author":"T Yasuhiro","year":"2017","unstructured":"Yasuhiro T, Sawada W, Klein C, et al. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO\/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO\/GS-4059 in combination with rituximab. Leuk Lymphoma. 2017;58(3):699\u2013707.","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"1318_CR9","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1182\/blood.V128.22.5116.5116","volume":"128","author":"Jamie Bates","year":"2016","unstructured":"Bates J, Kusam S, Tannheimer S, et al. The combination of a BET inhibitor (GS-5829) and a BTK inhibitor (GS-4059) potentiates DLBCL cell line cell death and reduces expression of MYC, IL-10, and IL-6 in vitro [abstract no. 5116]. Blood. 2016;128(22).","journal-title":"Blood"},{"key":"1318_CR10","doi-asserted-by":"publisher","first-page":"100201","DOI":"10.1016\/j.bonr.2019.100201","volume":"10","author":"Y Ariza","year":"2019","unstructured":"Ariza Y, Murata M, Ueda Y, et al. Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption. Bone Rep. 2019;10:100201.","journal-title":"Bone Rep"},{"issue":"Supplement_1","key":"1318_CR11","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1182\/blood-2019-123362","volume":"134","author":"Motoo Nagane","year":"2019","unstructured":"Nagane M, Narita Y, Mishima K, et al. Phase 1\/2 study of tirabrutinib (ONO\/GS-4059), a next-generation bruton's tyrosine kinase (BTK) inhibitor, monotherapy in patients with relapsed\/refractory primary central nervous system lymphoma (PCNSL) [abstract no. 1586]. Blood. 2019;134(Suppl 1).","journal-title":"Blood"},{"issue":"Supplement_1","key":"1318_CR12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood-2019-124614","volume":"134","author":"Wataru Munakata","year":"2019","unstructured":"Munakata W, Sekiguchi N, Shinya R, et al. Phase 2 study of tirabrutinib (ONO\/GS-4059), a second-generation Bruton's tyrosine kinase inhibitor, monotherapy in patients with treatment-Naive or relapsed\/refractory Waldenstrom macroglobulinemia [abstract no. 345]. Blood. 2019;134(Suppl 1).","journal-title":"Blood"},{"issue":"Supplement_1","key":"1318_CR13","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1182\/blood-2019-130912","volume":"134","author":"Nadine Kutsch","year":"2019","unstructured":"Kutsch N, Pallasch C, Decker T, et al. A prospective, open-label, multicenter, phase 2 trial to evaluate the safety and efficacy of the combination of tirabrutinib (ONO\/GS-4059) and idelalisib with and without obinutuzumab in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) [abstract no. 3047]. Blood. 2019;134(Suppl 1).","journal-title":"Blood"},{"issue":"Supplement_1","key":"1318_CR14","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1182\/blood-2019-130912","volume":"134","author":"Nadine Kutsch","year":"2019","unstructured":"Kutsch N, Pallasch C, Tausch E, et al. A prospective, open-label, multicenter, phase 2 trial to evaluate the safety and efficacy of the combination of tirabrutinib (ONO\/GS-4059) and entospletinib with and without obinutuzumab in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) [abstract no. 4297]. Blood. 2019;134(Suppl 1).","journal-title":"Blood"},{"key":"1318_CR15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-3504","author":"AV Danilov","year":"2020","unstructured":"Danilov AV, Herbaux C, Walter HS, et al. Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2020. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3504.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1318_CR16","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/cas.13983","volume":"110","author":"W Munakata","year":"2019","unstructured":"Munakata W, Ando K, Hatake K, et al. Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019;110(5):1686\u201394.","journal-title":"Cancer Sci"},{"issue":"4","key":"1318_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","volume":"127","author":"HS Walter","year":"2016","unstructured":"Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411\u20139.","journal-title":"Blood"},{"issue":"20","key":"1318_CR18","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2017-02-765115","volume":"129","author":"HS Walter","year":"2017","unstructured":"Walter HS, Jayne S, Rule SA, et al. Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO\/GS-4059. Blood. 2017;129(20):2808\u201310.","journal-title":"Blood"},{"key":"1318_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0658-7","author":"SA Rule","year":"2019","unstructured":"Rule SA, Cartron G, Fegan C, et al. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS\/ONO-4059). Leukemia. 2019. https:\/\/doi.org\/10.1038\/s41375-019-0658-7.","journal-title":"Leukemia"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01318-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01318-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01318-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T23:30:12Z","timestamp":1620343812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01318-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01318-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"7 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd.\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}